arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Dare Bioscience, Inc.

DARE
$1.34 0.00 (-0.37%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
26 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Dare Bioscience, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $15.0M
Dividend Yield
Revenue Growth 10429.4%
Op. Margin None
ROIC -476.8%
FCF / Share $-0.92
Trailing P/E
Price / Book 6.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.03M
↑ +10429.4%
Net Income Profit after all expenses
$-13.40M
↓ -230.6%
FCF / Share Free cash flow per share
$-0.92
↓ -259.3%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -476.8% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.77x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters